Journal Home
Search for

Volume 215, Issue 1, Pages 108-116 (30 October 2009)


View previous. 16 of 21 View next.

Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis

Thor Petersena, Anné Møller-Larsenb, Steffen Thielb, Tomasz Brudekb, Troels Krarup Hansenc, Tove ChristensenbCorresponding Author Informationemail address

Received 6 July 2009; received in revised form 26 August 2009; accepted 28 August 2009. published online 22 September 2009.

Abstract 

The effects of treatment of multiple sclerosis patients with IFN-β on elements in the innate and adaptive immune response were analysed in a longitudinal study. We demonstrate significant decreases in anti-Envelope antibody reactivity for the two closely related Gammaretroviral human endogenous retroviruses (HERVs), HERV-H and HERV-W, as a consequence of IFN-β therapy, closely linked to efficacy of therapy/low disease activity. We also show strong indications of a protective effect of high levels of two components in the innate pathogen-associated molecular pattern recognition: mannan-binding lectin (MBL), and MBL-associated serine protease 3 (MASP-3).

Serum levels of typical Th1- and Th2-related, MS-relevant cytokines were also monitored. Overall both Th1- and Th2-associated cytokines were modestly, albeit significantly up-regulated, notably IL-2 and TNF-α (MS patients with inactive disease), as well as IL-4 and, to some extent IL-10 (no increase in IL-10 for MS patients with active disease (non-responders)). We found no overall changes in Th1/Th2 ratios.

Our results support that HERV-H/HERV-W and the antiviral immune response may play a role in MS development, and that these HERVs have potential as biomarkers for disease activity.

a Department of Neurology, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark

b Institute of Medical Microbiology and Immunology, Bartholin Building, University of Aarhus, DK-8000 Aarhus C, Denmark

c Immunoendocrine Research Unit, Medical Department M (Diabetes and Endocrinology) and Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Aarhus, Denmark

Corresponding Author InformationCorresponding author.

PII: S0165-5728(09)00338-5

doi:10.1016/j.jneuroim.2009.08.015


View previous. 16 of 21 View next.